Elevation of HDL-C in response to statin treatment is involved in the regression of carotid atherosclerosis

Journal of Atherosclerosis and Thrombosis

Volumn 21, Issue 10, 2014, Pages 1055-1065

  Ishigaki, Yasushi ^a   Kono, Suminori ^b,d   Katagiri, Hideki ^a   Oka, Yoshitomo ^a   Oikawa, Shinichi ^c  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d NATIONAL INSTITUTE OF HEALTH AND NUTRITION   (Japan)

Author keywords

Carotid intima media thickness; HDL C; Statin; Type 2 diabetes

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGED; BLOOD; CAROTID ARTERY DISEASES; COMPLICATION; CONTROLLED STUDY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CAROTID ARTERY DISEASES; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84908221654     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.22095     Document Type: Article

References (42)

1. Kannel WB, McGee DL: Diabetes and cardiovascular disease. The framingham study. JAMA, 1979; 241: 2035-2038
2. Doi Y, Ninomiya T, Hata J, Fukuhara M, Yonemoto K, Iwase M, Iida M, Kiyohara Y: Impact of glucose tolerance status on development of ischemic stroke and coronary heart disease in a general japanese population: The hisayama study. Stroke, 2010; 41: 203-209
3. Sone H, Tanaka S, Iimuro S, Oida K, Yamasaki Y, Oikawa S, Ishibashi S, Katayama S, Ohashi Y, Akanuma Y, Yamada N: Serum level of triglycerides is a potent risk factor comparable to ldl cholesterol for coronary heart disease in japanese patients with type 2 diabetes: Subanalysis of the japan diabetes complications study (jdcs). J Clin Endocrinol Metab, 2011; 96: 3448-3456
4. Oikawa S, Kita T, Mabuchi H, Matsuzaki M, Matsuzawa Y, Nakaya N, Saito Y, Sasaki J, Shimamoto K, Itakura H: Risk of coronary events in japanese patients with both hypercholesterolemia and type 2 diabetes mellitus on lowdose simvastatin therapy: Implication from japan lipid intervention trial (j-lit). Atherosclerosis, 2007; 191: 440-446
5. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United kingdom prospective diabetes study (ukpds: 23). BMJ, 1998; 316: 823-828
6. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C: Efficacy of cholesterollowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet, 2008; 371: 117-125
7. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK, Jr.: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular health study collaborative research group. N Engl J Med, 1999; 340: 14-22
8. Folsom AR, Eckfeldt JH, Weitzman S, Ma J, Chambless LE, Barnes RW, Cram KB, Hutchinson RG: Relation of carotid artery wall thickness to diabetes mellitus, fasting glucose and insulin, body size, and physical activity. Atherosclerosis risk in communities (aric) study investigators. Stroke, 1994; 25: 66-73
9. Furberg CD, Adams HP, Jr., Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA, et al.: Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic carotid artery progression study (acaps) research group. Circulation, 1994; 90: 1679-1687
10. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE: Common carotid intima-media thickness and risk of stroke and myocardial infarction: The rotterdam study. Circulation, 1997; 96: 1432-1437
11. Touboul PJ, Elbaz A, Koller C, Lucas C, Adrai V, Chedru F, Amarenco P: Common carotid artery intima-media thickness and brain infarction: The etude du profil genetique de l’infarctus cerebral (genic) case-control study. The genic investigators. Circulation, 2000; 102: 313-318
12. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H: Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab, 1998; 83: 1818-1820
13. Lonn E, Yusuf S, Dzavik V, Doris C, Yi Q, Smith S, Moore-Cox A, Bosch J, Riley W, Teo K: Effects of ramipril and vitamin e on atherosclerosis: The study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin e (secure). Circulation, 2001; 103: 919-925
14. Kodama M, Yamasaki Y, Sakamoto K, Yoshioka R, Matsuhisa M, Kajimoto Y, Kosugi K, Ueda N, Hori M: Antiplatelet drugs attenuate progression of carotid intimamedia thickness in subjects with type 2 diabetes. Thromb Res, 2000; 97: 239-245
15. Huang Y, Li W, Dong L, Li R, Wu Y: Effect of statin therapy on the progression of common carotid artery intimamedia thickness: An updated systematic review and meta-analysis of randomized controlled trials. J Atheroscler Thromb, 2013; 20: 108-121
16. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y: Primary prevention of cardiovascular disease with pravastatin in japan (mega study): A prospective randomised controlled trial. Lancet, 2006; 368: 1155-1163
17. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr., Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Jr., Stone NJ: Implications of recent clinical trials for the national cholesterol education program adult treatment panel iii guidelines. Circulation, 2004; 110: 227-239
18. Nohara R, Daida H, Hata M, Kaku K, Kawamori R, Kishimoto J, Kurabayashi M, Masuda I, Sakuma I, Yamazaki T, Yokoi H, Yoshida M: Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in japanese patients: Justification for atherosclerosis regression treatment (jart) study. Circ J, 2012; 76: 221-229
19. Okimoto H, Ishigaki Y, Koiwa Y, Hinokio Y, Ogihara T, Suzuki S, Katagiri H, Ohkubo T, Hasegawa H, Kanai H, Oka Y: A novel method for evaluating human carotid artery elasticity: Possible detection of early stage atherosclerosis in subjects with type 2 diabetes. Atherosclerosis, 2008; 196: 391-397
20. Yamasaki Y, Katakami N, Furukado S, Kitagawa K, Nagatsuka K, Kashiwagi A, Daida H, Kawamori R, Kaku K: Long-term effects of pioglitazone on carotid atherosclerosis in japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. J Atheroscler Thromb, 2010; 17: 1132-1140
21. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 1972; 18: 499-502
22. Amarenco P, Labreuche J, Lavallee P, Touboul PJ: Statins in stroke prevention and carotid atherosclerosis: Systematic review and up-to-date meta-analysis. Stroke, 2004; 35: 2902-2909
23. Saito Y, Yamada N, Teramoto T, Itakura H, Hata Y, Nakaya N, Mabuchi H, Tushima M, Sasaki J, Ogawa N, Goto Y: A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis, 2002; 162: 373-379
24. Beishuizen ED, van de Ree MA, Jukema JW, Tamsma JT, van der Vijver JC, Meinders AE, Putter H, Huisman MV: Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease. Diabetes Care, 2004; 27: 2887-2892
25. Campbell CY, Rivera JJ, Blumenthal RS: Residual risk in statin-treated patients: Future therapeutic options. Curr Cardiol Rep, 2007; 9: 499-505
26. Ashen MD, Blumenthal RS: Clinical practice. Low hdl cholesterol levels. N Engl J Med, 2005; 353: 1252-1260
27. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC: Hdl cholesterol, very low levels of ldl cholesterol, and cardiovascular events. N Engl J Med, 2007; 357: 1301-1310
28. Tani S, Nagao K, Hirayama A: Hmg-coa reductase inhibitor (statin) therapy and coronary atherosclerosis in japanese subjects: Role of high-density lipoprotein cholesterol. Am J Cardiovasc Drugs, 2011; 11: 411-417
29. Sekikawa A, Ueshima H, Zaky WR, Kadowaki T, Edmundowicz D, Okamura T, Sutton-Tyrrell K, Nakamura Y, Egawa K, Kanda H, Kashiwagi A, Kita Y, Maegawa H, Mitsunami K, Murata K, Nishio Y, Tamaki S, Ueno Y, Kuller LH: Much lower prevalence of coronary calcium detected by electron-beam computed tomography among men aged 40-49 in japan than in the us, despite a less favorable profile of major risk factors. Int J Epidemiol, 2005; 34: 173-179
30. Satoh H, Tomita K, Fujii S, Kishi R, Tsutsui H: Lower high-density lipoprotein cholesterol is a significant and independent risk for coronary artery disease in japanese men. J Atheroscler Thromb, 2009; 16: 792-798
31. Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S: A 52-week, randomized, open-label, parallelgroup comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther, 2008; 30: 1089-1101
32. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, Najib-Fruchart J, Glineur C, Staels B: Statin-induced inhibition of the rho-signaling pathway activates pparalpha and induces hdl apoa-i. J Clin Invest, 2001; 107: 1423-1432
33. Maejima T, Yamazaki H, Aoki T, Tamaki T, Sato F, Kitahara M, Saito Y: Effect of pitavastatin on apolipoprotein a-i production in hepg2 cell. Biochem Biophys Res Commun, 2004; 324: 835-839
34. Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ: Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (radiance 2 study): A randomised, double-blind trial. Lancet, 2007; 370: 153-160
35. Davignon J: Beneficial cardiovascular pleiotropic effects of statins. Circulation, 2004; 109: 39-43
36. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH: Joint effects of serum triglyceride and ldl cholesterol and hdl cholesterol concentrations on coronary heart disease risk in the helsinki heart study. Implications for treatment. Circulation, 1992; 85: 37-45
37. Enomoto M, Adachi H, Hirai Y, Fukami A, Satoh A, Otsuka M, Kumagae S, Nanjo Y, Yoshikawa K, Esaki E, Kumagai E, Ogata K, Kasahara A, Tsukagawa E, Yokoi K, Ohbu-Murayama K, Imaizumi T: Ldl-c/hdl-c ratio predicts carotid intima-media thickness progression better than hdl-c or ldl-c alone. J Lipids, 2011; 2011: 549137
38. Kurebayashi N, Yoshikawa D, Ishii H, Sato B, Ando H, Okada T, Hayakawa S, Okumura N, Isobe S, Takeshita K, Hayashi M, Uetani T, Amano T, Murohara T: Impact of the lowto high-density lipoprotein cholesterol ratio on composition of angiographically ambiguous left main coronary artery plaque. Circ J, 2011; 75: 1960-1967
39. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN: Arbiter: Arterial biology for the investigation of the treatment effects of reducing cholesterol: A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation, 2002; 106: 2055-2060
40. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M: Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome--serial intravascular ultrasound observations from the japan assessment of pitavastatin and atorvastatin in acute coronary syndrome trial (the japan-acs trial). Circ J, 2010; 74: 1165-1174
41. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ: Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med, 2008; 359: 2195-2207
42. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I: Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet, 2010; 375: 735-742